Refine by
Clinical Trial Articles & Analysis
1,562 news found
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), an autologous stem cell company developing and commercializing VesCell™ (ACP-01), announces the appointment of a seasoned commercial team encompassing marketing, sales, e-commerce and patient care communications, in compliance with federal and state regulations. The appointments enable Hemostemix to sell VesCell™ in Florida to ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
The ANDA contains information used for the review and approval of a generic drug product, and does not typically require preclinical and clinical trial data, but rather requires the inclusion of information on bioequivalence to the RLD. ...
Endotoxin free silver nanoparticles are characterized by high purity and low endotoxin levels, ideal for use in in vivo studies and clinical trials with a low risk of adverse effects. CD Bioparticles provides a range of endotoxin free silver nanoparticles with sizes varying from 10 nm to 100 nm. ...
As of the latest research, several experimental gene therapies for glaucoma are in various stages of development, from preclinical studies to early-phase clinical trials. As an innovative ophthalmic disease research company with a wide range of services in basic research, drug development, and preclinical studies, Ace Therapeutics has expanded its portfolio to ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...
Major pharmaceutical companies are increasingly incorporating LNP technology into their clinical trials, highlighting its promise in mRNA-based vaccines and nucleic acid therapeutics. ...
The research is a retrospective, multimodal analysis of the POSEIDON Phase 3 clinical trial (NCT03164616). This trial originally demonstrated that the combination of tremelimumab, durvalumab, and chemotherapy significantly increases progression-free survival (PFS) and overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, ...
The process of antipsychiatric drug development typically involves several stages, including identifying potential drug targets, conducting preclinical research to test the safety and efficacy of potential drug candidates, and then moving on to clinical trials to further evaluate the drug’s effectiveness and safety in human subjects. ...
Together, SOPHiA GENETICS and Boundless Bio pioneered the ecDNA Solution (ECS) algorithm to detect the presence of ecDNA using routine clinical next-generation sequencing (NGS) data. ECS is the first ecDNA clinical trial assay and was designed by SOPHiA GENETICS in alignment with FDA guidelines as an Investigational Use Only ...
Additionally, Semaglutide has been shown to delay gastric emptying, leading to a prolonged sense of fullness and reduced appetite, ultimately contributing to significant weight loss in clinical trials. The efficacy of Semaglutide has been extensively studied in numerous phase 3 clinical trials, with consistently impressive ...
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API ...
Monoclonal antibodies (mAbs) targeting the CGRP pathway, including erenumab, galcanezumab and fremanezumab, have shown promise in clinical trials and real-life studies. Initially, the European Headache Federation recommended treatment with CGRP(-R) mAbs for 6 to 12 months, followed by interruption. ...
The production method in accordance with good manufacturing practice (GMP) is under development in order to initiate the first clinical trial. Other candidates have already been constructed and are undergoing preclinical evaluation, against HPV induced cancers or infectious diseases. ...
ByOncoVITA
It is a critical process for devices that are being tested in clinical trials or pilot markets prior to full-scale production. If a manufacturer’s medical device is successful in a pilot market or clinical trial, it may be possible to move to full- scale production. ...
BySTEMart
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. ...
At present, we have completed approximately 60% of the enrollment of our randomized Phase 2 clinical trial that builds upon our successful Phase 1 trial. Our Phase 2 trial will compare outcomes of babies treated with the standard of care (SOC) plus Lomecel-BTM vs. the SOC alone. We expect this trial to finish ...
Several studies have shown that transfection of cancer cells with plasmids expressing wild-type P53 induces apoptosis and/or growth arrest. To date, several clinical trials have been completed using viral and non-viral vectors to deliver the P53 gene either alone or in combination with other therapeutic agents. ...
Plans were outlined for moving forward in the coming summer towards clinical trials in Australia of the antigen preparation together with a powerful adjuvant (a compound that enhances immune reactions in animals and humans). ...